🔴 AIM ImmunoTech is trading 5.5% down today with no clear company-specific catalyst

AIM ImmunoTech is trading 5.5% down at $0.24, with no clear company-specific announcement dated August 14, 2026 explaining the decline.

• Recent coverage centers on August 10 second-quarter results and progress toward Phase 3 development; the final DURIPANC patient milestone was announced August 3.
• Broader markets are modestly weaker, but S&P 500, Nasdaq Composite, and Dow Jones declines remain below 0.5%; trading activity and volume details were unavailable.